Cystinosis Market to Grow at a Substantial Growth Rate of 5.1% During the Forecast Period (2025-2034) | DelveInsight
The cystinosis therapeutic landscape remains dominated by established cysteamine-based treatments, with limited availability of next-generation, curative, or truly disease-modifying options. However, emerging therapies are gradually transforming the field by more directly targeting disease pathophysiology and overcoming key shortcomings of current standards of care. Pipeline candidates such as TTI-0102 and DFT383 highlight a shift toward enhanced systemic cystine control and potential disease modification, including strategies that improve cysteamine delivery and gene-based correction of the underlying CTNS defect.
LAS VEGAS, Jan. 21, 2026 /PRNewswire/ -- DelveInsight's Cystinosis Market Insights report includes a comprehensive understanding of current treatment practices, cystinosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Cystinosis Market Summary
Discover what will be the growth rate of cystinosis cases over the next decade @ https://www.delveinsight.com/sample-request/cystinosis-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Cystinosis Market
Cystinosis Market Analysis
Cystinosis Competitive Landscape
The cystinosis clinical trial landscape is steadily evolving, with a defined group of emerging therapies including TTI-0102 (Thiogenesis Therapeutics), DFT383 (Novartis), and others progressing through development.
Novartis' DFT383 is an experimental gene therapy for nephropathic cystinosis that aims to restore CTNS function and reduce lysosomal cystine buildup. Previously referred to as AVR-RD-04 or CTNS-RD-04, the asset was acquired from AVROBIO and is currently being assessed in a Phase I/II study in pediatric patients, following initial evaluation in adults. Mentions of Papillon Therapeutics relate to shared scientific origins and the validation of the underlying platform, rather than to program ownership or development responsibility.
Thiogenesis Therapeutics' TTI-0102 is an orally administered cysteamine prodrug designed to address the shortcomings of conventional thiol-based treatments. Developed under the 505(b)(2) regulatory pathway, the candidate leverages established cysteamine safety data while demonstrating favorable tolerability at elevated doses, sustained cystine reduction, and preserved antioxidant effects. Classified as a New Chemical Entity, TTI-0102 is eligible for five years of market exclusivity and is progressing toward a pivotal Phase III study, with IND filing anticipated in the second half of 2026.
The anticipated launch of these emerging therapies are poised to transform the cystinosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the cystinosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which companies are developing cystinosis treatments @ Cystinosis Drugs Market
Recent Developments in the Cystinosis Market
What is Cystinosis?
Cystinosis is a rare, inherited metabolic disorder caused by a defect in the CTNS gene, which leads to the abnormal buildup of the amino acid cystine within cells. Because cystine cannot be properly transported out of lysosomes, it accumulates and forms crystals that damage tissues and organs over time. The kidneys are usually affected first, particularly the proximal tubules, leading to Fanconi syndrome and symptoms such as excessive urination, dehydration, poor growth, and electrolyte imbalances in early childhood. If left untreated, cystinosis can progress to kidney failure and cause complications in other organs, including the eyes, thyroid, muscles, and nervous system. While there is no cure, early diagnosis and treatment with cystine-depleting therapies can significantly slow disease progression and improve long-term outcomes.
Cystinosis Epidemiology Segmentation
The cystinosis epidemiology section provides insights into the historical and current cystinosis patient pool and forecasted trends for the leading markets. In 2024, DelveInsight estimated approximately 1,700 prevalent cases of cystinosis in the US, accounting for a substantial share of the total cases across the 7MM.
The cystinosis treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Cystinosis Market Forecast Report Metrics
Details
Study Period
2020–2034
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Cystinosis Market CAGR
5.1 %
Cystinosis Market Size in 2024
USD 250 Million
Key Cystinosis Companies
Thiogenesis Therapeutics, Novartis, Amgen, Chiesi Farmaceutici, Recordati Rare Diseases, Viatris, and others
Key Cystinosis Therapies
TTI-0102, DFT383, PROCYSBI, CYSTADROPS, CYSTAGON/ NICYSTAGON, and others
Scope of the Cystinosis Market Report
Download the report to understand what will drive the cystinosis market in the next decade @ Cystinosis Market Drivers
Table of Contents
1
Cystinosis Market Key Insights
2
Cystinosis Market Report Introduction
3
Cystinosis Market Overview at a Glance
3.1
Market Share (%) Distribution of Cystinosis by Therapies in the 7MM in 2024
3.2
Market Share (%) Distribution of Cystinosis by Therapies in the 7MM in 2034
4
Executive Summary
5
Key Events
6
Disease Background and Overview
6.1
Introduction
6.2
Classification
6.3
Etiology
6.4
Pathophysiology
6.5
Signs and Symptoms
6.6
Diagnosis
6.7
Treatment and Management
6.8
Diagnosis and Treatment Guidelines
7
Epidemiology and Market Forecast Methodology
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale
8.2.1
Prevalent Cases of Cystinosis
8.2.2
Diagnosed Prevalent Cases of Cystinosis
8.2.3
Type-specific Diagnosed Prevalent Cases of Cystinosis
8.3
Total Diagnosed Prevalent Cases of Cystinosis in the 7MM
8.4
The US
8.4.1
Total Prevalent Cases of Cystinosis in the US
8.4.2
Total Diagnosed Prevalent Cases of Cystinosis in the US
8.4.3
Type-specific Diagnosed Prevalent Cases of Cystinosis in the US
8.5
EU4 and the UK
8.6
Japan
9
Cystinosis Patient Journey
10
Marketed Cystinosis Drugs
10.1
Key Cross of Marketed Therapies
10.2
PROCYSBI (cysteamine bitartrate): Amgen/Chiesi Farmaceutici
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Summary of Pivotal Trials
10.2.5
Analyst Views
10.3
CYSTADROPS (cysteamine hydrochloride): Recordati Rare Diseases/Viatris
10.4
CYSTARAN (cysteamine hydrochloride): Leadiant Biosciences
10.5
CYSTAGON/NICYSTAGON (cysteamine bitartrate): Viatris
List to be continued in the final report….
11
Emerging Cystinosis Therapies
11.1
Key Cross Competition
11.2
DFT383: Novartis
11.2.1
Product Description
11.2.2
Other Development Activities
11.2.3
Clinical Development
11.2.3.1
Clinical Trials Information
11.2.4
Safety and Efficacy
11.2.5
Analyst Views
11.3
TTI-0102: Thiogenesis Therapeutics
List to be continued in the final report….
12
Cystinosis Market– 7MM Market Analysis
12.1
Key Findings
12.2
Key Cystinosis Market Forecast Assumptions
12.3
Cystinosis Market Outlook
12.4
Attribute Analysis
12.5
Total Market Size of Cystinosis in the 7MM
12.6
Market Size of Cystinosis by Therapies in the 7MM
12.7
The United States Cystinosis Market Size
12.7.1
Total Market Size of Cystinosis in the US
12.7.2
Market Size of Cystinosis by Therapies in the US
12.8
EU4 and the UK Cystinosis Market Size
12.9
Japan Cystinosis Market Size
13
Key Opinion Leaders' Views on Cystinosis
14
Cystinosis Market Unmet Needs
15
Cystinosis Market SWOT Analysis
16
Cystinosis Market Access and Reimbursement
16.1
The United States
16.2
In EU4 and the UK
16.3
Japan
16.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
16.5
Cystinosis Market Access and Reimbursement
17
Acronyms and Abbreviations
18
Bibliography
19
Cystinosis Market Report Methodology
Related Reports
Cystinosis Clinical Trial Analysis
Cystinosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cystinosis companies, including AVROBIO, Birch Therapeutics, Nacuity Pharmaceuticals, Thiogenesis Therapeutics, Novartis, Amgen, Chiesi Farmaceutici, Recordati Rare Diseases, Viatris, among others.
Nephropathic Cystinosis Market
Nephropathic Cystinosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nephropathic cystinosis companies, including Horizon Therapeutics PLC, Mylan N.V., Chiesi Farmaceutici SpA, Recordati Rare Disease, AVROBIO Inc., Leadiant Biosciences Inc., Eloxx Pharmaceuticals, GSK, among others.
Nephropathic Cystinosis Clinical Trial Analysis
Nephropathic Cystinosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nephropathic cystinosis companies, including Horizon Therapeutics PLC, Mylan N.V., Chiesi Farmaceutici SpA, Recordati Rare Disease, AVROBIO Inc., Leadiant Biosciences Inc., Eloxx Pharmaceuticals, GSK, among others.
End-stage Renal Disease Market
End-stage Renal Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ESRD companies, including Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP